A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 (NCT06240728)
A Phase 1a/1b Dose Escalation and Dose Expansion Study of NPX887 in Participants With Solid Tumor Malignancies Known to Express B7-H7/HHLA2
🩺 Plain-English Summary (8th-Grade Level)
NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
- Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
- Albert Einstein Medical College Montefiore Medical Center — The Bronx, New York
- MD Anderson Cancer Center — Houston, Texas
- Next Oncology — San Antonio, Texas
- NEXT Oncology-Fairfax — Fairfax, Virginia
- Severance Hospital, Yonsei University Health System — Seoul,
- Samsung Medical Center — Seoul,
📞 Contact the Study Coordinator
Phone: (855) 694-6725
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Malignant Neoplasm
- Cryoablation for the Treatment of Metastatic Cancer — Houston, Texas
- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II) — Houston, Texas
- Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases — Houston, Texas
- NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies — La Jolla, California
- Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer — Buffalo, New York
Explore by condition: All Metastatic Malignant Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.